BlueCrest Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

BlueCrest Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-425	Closed	-$350K	–	254
2023 Q3	$350K	Buy	+425	New	+$334K	0.02%	215
2018 Q4	–	Sell	-2,710	Closed	-$1.09M	–	1322
2018 Q3	$1.09M	Buy	+2,710	New	+$1.03M	0.03%	415
2016 Q2	–	Sell	-3,019	Closed	-$1.09M	–	1011
2016 Q1	$1.09M	Buy	+3,019	New	+$1.24M	0.07%	358

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlueCrest Capital Management's REGN Position: Q4 2023 in Review

BlueCrest Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2023, closing a stake of 425 shares — an estimated $350K sold.

BlueCrest Capital Management first reported a position in REGN in Q1 2016 and held it in 3 quarters. The position peaked at $1.09M in Q3 2018. 1,272 funds tracked by Wall St. Rank hold REGN as of Q4 2023.

BlueCrest Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
BlueCrest Capital Management sold 425 Regeneron Pharmaceuticals shares in Q4 2023, an estimated $350K.
BlueCrest Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2016 and held it in 3 quarters.
BlueCrest Capital Management's Regeneron Pharmaceuticals position peaked at $1.09M in Q3 2018.
1,272 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2023.

Based on BlueCrest Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.